Visiongain Report Claims There is Huge Potential Within the $22bn Global Checkpoint Inhibitors for Anti-Cancer Treatment Market

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs

News provided by

Aug 02, 2019, 05:00 ET

LONDON, Aug. 2, 2019 /PRNewswire/ -- The global checkpoint inhibitors for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 152-page Visiongain report you will receive 72 tables and 32 figures– all unavailable elsewhere.

The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/checkpoint-inhibitors-for-anti-cancer-treatment-market-2019-2029/#download_sampe_div

Report Scope

• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029

• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:
• Yervoy (ipilimumab)
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)

• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:
• CTLA-4 Inhibitors
• PD-1 Inhibitors
• Pipeline Drugs

• Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:
• U.S.
• EU: Germany, France, Italy, U.K., Spain
• Japan
• APAC

• Profiles of the selected leading companies:
• AstraZeneca, Plc
• Bristol-Myers Squibb Co.
• Celldex Therapeutics, Inc.
• Incyte Corporation
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Roche Holding AG

• The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis

• A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market

• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2018 to 2029?
• What are the leading national market potentials from 2018 to 2029?
• How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
• What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
• What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
• How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/checkpoint-inhibitors-for-anti-cancer-treatment-market-2019-2029/

Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.

Companies covered in the report include:

AbbVie
Abramson Cancer Center
Admune Therapeutics
Aduro Biotech
Advaxis, Inc.
Agenus Inc.
Agilent Technologies
Alcon
Amgen
Amplimmune
AnaptysBio
Apexigen, Inc.
AREVA Med
ARIAD Pharmaceuticals, Inc.
Array BioPharma
AstraZeneca
Aurigene Discovery Technologies
Basilea Pharmaceutica Ltd.
BeiGene
Bristol-Myers Squibb
Calithera Biosciences Inc.
cCAM Biotherapeutics
Celgene
Celldex Therapeutics Inc.
Chugai
Clal Biotech
Clovis Oncology, Inc.
CoStim Pharmaceuticals
CureTech, Ltd.
Curis, Inc.
Daiichi Sankyo Company, Limited
Dako
DNAtrix
Dynavax
Eddingpharm
Eisai Co., Ltd.
Eli Lilly
Exelixis, Inc.
GE Healthcare
GeneCentric Diagnostics, Inc.
Heptares Therapeutics
IBM
Immune Design
Immunocore Limited
Immutep
Incyte
Innate Pharma
Inovio Pharmaceuticals
IOmet Pharma Ltd.
Janssen Biotech, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin
MacroGenicS Inc.
Medarex
MedImmune
Medivation, Inc
Merck & Co.
Merus N.V.
Moderna Therapeutics
Moffitt Cancer Center
MS
NanoString Technologies, Inc.
NEC Corporation
NewLink Genetics
Novartis
Oncothyreon Inc.
Ono Pharmaceutical
Peregrine Pharmaceuticals
Pfizer, Inc.
Plexxikon Inc.
Prima Biomed
Regeneron Pharmaceuticals
Roche
Sandoz
Sanofi
Seattle Genetics, Inc.
Sosei Group Corporation
Surface Oncology
Syndax Pharmaceuticals
Syros Pharmaceuticals, Inc.
TARIS Biomedical LLC
TESARO, Inc.
TetraLogic Pharmaceuticals Corporation
Transgene SA
Western Oncolytics
Xencor

List of Organisations Mentioned in the Report
Cancer Research Institute
Central Social Insurance Medical Council
Data Monitoring Committee
Early Access to Medicines Scheme
European Cancer Congress
European Medicines Agency
European Organisation for Research and Treatment of Cancer
MD Anderson Cancer Center
Medicines and Healthcare Products Regulatory Agency
Ministry of Health, Labour, and Welfare
National Cancer Institute
National Institute for Health and Clinical Excellence
QIMR Berghofer Medical Research Institute
University of Pittsburgh
Yamaguchi University